Yasin Keshvargar
Lawyers
Filters
Editas Medicine $125 million follow-on offering
We advised the joint book-running managers on the offering
newcleo combination with NewHold Investment Corp III and PIPE financing
We are advising newcleo on the transaction with the SPAC
Sabre $150 million private placement of exchangeable notes
We advised Sabre on the private placement
GH Research $200 million at-the-market offering
We advised GH Research on the establishment of the at-the-market program
Tempus AI $460 million convertible senior notes offering
We advised the representatives of the several initial purchasers on the offering
CellCentric $220 million Series D financing round
We advised Venrock Healthcare Capital Partners
GH Research $117.5 million follow-on offering
We advised GH Research on the offering
Avalyn Pharma $300 million IPO
We advised the underwriters on the IPO
Vistra $4 billion senior notes offering
We advised the representatives of the several underwriters on the offering
Revolution Medicines $2.2 billion common stock and convertible notes offerings
We advised the underwriters on the concurrent offerings